Introduction {#s1}
============

Prostate cancer is the most prevalent cancer among men and the third most common cause of death among men \[[@R01]\]. For many years clinicians have tried several strategies to improve outcomes in patients with localized prostate cancer. Patients with high risk prostate cancer \[defined as a PSA \> 20, ≥ cT2b, Gleason score ≥ 8\] have received androgen suppression therapy (AST) in addition to definitive radiation therapy. There have been multiple randomized trials that have shown a benefit in biochemical control and some with an overall survival benefit to the combined use of AST and pelvic radiation therapy \[[@R02]-[@R06]\]. However, a different method to potentially further optimize outcomes is to escalate the dose of radiation. Multiple randomized studies have shown an improvement in progression free survival and failure free survival both in Northern America and in Europe when dose to the prostate is increased \[[@R07]-[@R14]\]. However, the limitation inherent to this technique is the normal tissue toxicity, particularly doses to the small bowel.

Intensity modulated radiation treatment (IMRT) has been used for dose shaping in prostate cancer, with what appears to be good clinical outcomes while respecting \[deleted regarding\] normal tissue toxicity \[[@R15]\]. IMRT may also allow dose escalation to be applied to the at-risk lymph nodes of high risk prostate cancer patients, as it may allow for sparing of the small bowel. A few institutions have attempted to use IMRT as a method of sparing bowel, the dose limiting structure of pelvic RT, while treating pelvic nodes in prostate cancer \[[@R16]-[@R18]\]. In a recent publication, researchers in Norway found that the use of IMRT improves target coverage and reduces normal tissue dose \[order of these two phrases were swapped\], which may correlate to an improved toxicity profile \[[@R19]\]. In Italy they have also looked into the dose-volume effect of radiation on bowel toxicity and they found that an IMRT approach drastically reduced the incidence of acute bowel toxicity \[[@R20]\]. In the UK, researchers found acceptably low bowel toxicity with dose escalation up to 55 Gy to the pelvis \[[@R18]\].

At our institution, we implemented a Phase I clinical trial evaluating the use of IMRT in the high risk patient group with the aim of escalating the dose to the pelvic lymph nodes. The primary objective was to determine the feasibility of treating pelvic lymph nodes with IMRT. The secondary objective was to evaluate long-term effects and toxicity following IMRT dose escalation to the pelvic nodes. In this report, we present our early experiences in target volume definitions and resulting dose distributions and toxicities.

Materials and Methods {#s2}
=====================

Patient characteristics {#s2a}
-----------------------

Between February 2006 and May 2008, 12 patients were prospectively enrolled on an institutional review board approved Phase I study using intensity modulated radiation therapy (IMRT) to irradiate the pelvic and lower para-aortic nodes and the prostate and seminal vesicles in patients with high risk prostate cancer. Eligible patients were greater than 18 years of age and less than 90 years of age, ECOG performance status of ≤ 2, pathology report confirming adenocarcinoma of the prostate, risk of lymph node metastasis greater than or equal to15% as defined by the Partin tables \[[@R21]\] or biopsy proven positive lymph nodes, tumor must be visible on MRI, and with no history of prior surgery, radiation or chemotherapy for prostate cancer (with the exception of hormonal therapy). Exclusion criteria include cognitively impaired patients who cannot give informed consent, patients with metastatic disease beyond the pelvis, any contraindication to biopsies, any contraindication to having an MRI performed and any pre-existing and active prostatitis or proctitis.

Treatment specifics {#s2b}
-------------------

Procedures for simulation and planning were identical for all patients. Prior to CT simulation, patients had four gold fiducial markers (CIVCO, 1.2 x 3 mm fiducials (MT-NW-887-814) placed with the assistance of APT MRI: manipulator for access to prostate tissue under magnetic resonance imaging guidance (APT-MRI) \[[@R22]\]. Each patient was simulated 4 - 5 days after the fiducial marker placement to allow the fiducials to settle in the prostate. For simulation, patients were placed in the supine position with leg immobilization and a planning CT scan was performed with 0.3 cm spacing between slices. The CT scans extended from T12 to the upper third of the femur. Patients were asked to come to the simulation and daily treatment with a "comfortably full" bladder; to ensure similar daily bladder fullness, the patients were asked to drink 1 - 2 cups of water 15 minutes prior to their treatment. Patient setup was monitored daily using fiducial marker localization.

Using the Eclipse treatment planning system (Varian Oncology Systems, Palo Alto, CA), the treating radiation oncologist contoured three sets of clinical target volumes, CTV1, CTV2 and CTV3. CTV1 consists of prostate, seminal vesicle and pelvic lymph nodes, CTV2 is the sum of prostate and seminal vesicle and CTV3 is the prostate. The contouring of the prostate was aided by a fused MRI performed on all patients prior to the CT simulation. The pelvic lymph node contours for CTV1 were defined as the aorta 2 cm proximal to the bifurcation, the common, internal and external iliac \[omitted "vessels are contoured"\] (plus 2 cm concentrically) to the level of the most superior slice of the seminal vesicle \[[@R23]\]. PTV1 was this previously mentioned volume in addition to PTV2 and PTV3. PTV2 and PTV3 were determined by applying a total margin of 9 mm around the CTV2 and CTV3, except posteriorly, where a 5 mm margin was used.

The treating radiation oncologist also outlined the relevant organs at risk (OARs), including the bladder, rectum, and small intestines. The bladder was outlined from apex to dome and the rectosigmoid flexure was applied as the cranial limit of the rectum and the anal verge as the caudal limit. The small intestinal volume was contoured superiorly to the level of PTV1, including all identifiable small intestines. These volumes were based on the planning scan only and no attempts were made to account actively for the motion of these organs.

The radiation course for all patients consisted of an initial IMRT plan delivering 45 Gy to the PTV1 followed by an IMRT plan delivering 9 Gy to the PTV2 and then another 21.6 Gy to the prostate only for a total dose of 75.6 Gy to the prostate all delivered in 1.8 Gy daily fractions, five days per week. Intensity modulation was achieved using the sliding window method and most patients were treated with a five-field or seven-field technique using 6MV X-ray beams. All treatment planning and optimization was performed using Eclipse. Patients were treated on one of two Varian Clinacs (2100EX2999); both are equipped with MLC-120 multi-leaf collimators. One is equipped with EPID (electronic portal imaging devices) and the second is equipped with EPID and OBI (On Board Imager). Daily setup is performed by taking a pair of orthogonal images and performing a 2D/2D match for the pelvic fields and fiducial marker matching when treating the cone-down fields.

The optimization constraints were given to achieve these priorities: first, at least 95% of the PTVs receiving the prescribed dose; second, less than 25% of the rectum receiving 70 Gy; third, less than 40% of the dose getting 65 Gy and less than 10 cc of small bowel receiving 55 Gy. Patient specific quality assurances were performed prior to the patient's treatment.

Analysis of dose-volume histogram {#s2c}
---------------------------------

Dose-volume histograms (DVHs) were calculated for all defined volumes (for example the PTVs, bladder, rectum, small intestine) from the sum plans in all twelve patients. In this paper we focus on analyzing the DVHs for the OARs rather than the PTVs.

Toxicity scoring {#s2d}
----------------

The NCI Common Toxicity Grading Criteria and RTOG toxicity scoring system were used to grade lower GI and GU morbidity during and after the course of treatment \[[@R24]\]. Patients were scheduled for weekly assessments of symptoms during the course of radiation therapy by the responsible oncologist. Acute effects were scored weekly during treatment and during the scheduled follow-up visits. In general the GI or GU symptoms that needed medical prescriptions were scored as Grade 2 or greater toxicity.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

At diagnosis, median age was 64 (range: 50 - 74 years of age), median PSA was 15.5 (range: 5.7 - 103) and median Gleason score 8 (range: Gleason 7 - 9). The details of the patients' characteristics are displayed in [Table 1](#T1){ref-type="table"}. The median follow-up time was 28 months (range: 17 - 49 months). Patients allowed on this trial were defined as high risk prostate cancers defined by the Partin tables (Partin 2001). All patients received neoadjuvant, concurrent and adjuvant hormonal therapy and pelvic, seminal vesicle, and prostate radiation therapy (RT).

###### Characteristics of Study Patients

  Characteristics      Value
  -------------------- ---------
  Number of patients   12
  Median age (years)   64
  Age range (years)    50 - 74
  Clinical stage       
    T1                 5
    T2                 6
    T3                 1
    T4                 0
    Tx                 0
  Gleason sum          
    ≤ 6                0
    7                  2
    8                  5
    9                  5
    10                 0
  PSA (ng/L)           
    \< 4               0
    4 - 10             3
    \> 10, \< 20       4
    \> 20              5

DVH analysis {#s3b}
------------

The median bladder volume is 126 cc, median bladder dose is 51.85 Gy and V60 bladder median was 22% range (16-41%), maximum dose of 79.04, and D40 54.49 Gy. The median rectal dose of 53.45; median max dose 77.72 Gy, median V65 15.05%, median V50 58.1%, median D25 60.11 Gy, median D50 52.26 Gy. The median small bowel dose is 25.8 Gy, median max dose 48.51 Gy, median D10 cc 47.18 Gy.

Adverse effects {#s3c}
---------------

No Grade 3 or higher GI adverse effects were observed among the patients either during treatment or during follow-up appointments. During treatment, Grade 2 GU toxicity was noted in 3/12 (25%) patients and Grade 2 GI toxicity was noted in 2/12 patients (16%). At a median of 31 months, Grade 2 GU toxicity was seen in 3/12 (25%) of patients and Grade 2 GI toxicity 1/12 (8%) patients. There were no acute or late grade 3 and 4 GU or GI toxicities. Refer to [Table 2](#T2){ref-type="table"} for details.

###### Toxicity Associated With Treatment

  Toxicity              Number of patients
  --------------------- --------------------
  Acute GU Grade 1, 2   8/12
  Acute GI Grade 1, 2   10/12
  Late GU Grade 1, 2    6/12
  Late GI Grade 1, 2    5/12

All patients were able to complete the full course of treatment and were followed closely, one patient was take off the protocol as he subsequently moved out of country and was unable to be followed as per the predetermined schedule ([Fig. 1](#F1){ref-type="fig"}).

![Axial View of Conformal IMRT Isodoses in Pelvis (a, b). Sagittal View of Conformal IMRT Isodoses in Pelvis (c)](wjon-03-016-g001){#F1}

Discussion {#s4}
==========

While dose escalation to the prostate has shown to improve outcomes, dose escalation to the pelvis has not been successful, secondary to increased rates of gastrointestinal toxicity \[[@R25]\]. Our study and cohort of patients is particularly encouraging because of the low incidence of GI/GU toxicity as compared to currently published reports. An older study has proposed that less than 78 cm^3^ of the small bowel should receive more than 45 Gy \[[@R25]\]. In Norway they found that the use of IMRT could critically decrease the dose to normal structures compared to 3D CRT. With the use of IMRT, they were able to administer 50 Gy to the pelvis, prostate and seminal vesicles with an additional 20 Gy to the prostate and seminal vesicles with low rates of toxicity \[[@R19]\]. In the United Kingdom, they have one of the largest studies to date using IMRT to dose escalate to the pelvis to 50 Gy and 55 Gy with a total of 70 Gy to the prostate; the toxicity rates are reasonable given the dose to the pelvis. They also evaluated their patients based on the bowel that was contoured and found RTOG acute Grade ≥ 2 to be 38% and 51% for patients who had \< 450 cc versus ≥ 450 cc bowel contoured \[[@R18]\]. Also of interest, this trial \[deleted had\] found that no one particular dose effect was apparent thus far for the 50 Gy and 55 Gy cohort as roughly the same numbers of patients had RTOG Grade 2 toxicity.

The RTOG 92-02 trial treated the pelvic lymph nodes to 45 Gy (no IMRT for the pelvic field) and 65 to 70 Gy to the prostate \[[@R05]\]. The EORTC 22,863 trial treated the pelvis to 50 Gy and 70 Gy to the prostate \[[@R26]\]. The toxicity outcomes are listed in [Table 3](#T3){ref-type="table"} \[[@R05], [@R27]\]. For our study we found that for acute Grade 1 and 2, GU and GI side effects were relatively less than what was seen in these studies using hormonal therapy and treatment to the pelvis in addition to the prostate and seminal vesicles ([Table 3](#T3){ref-type="table"}). In the previously referenced studies, where patients received equivalent or lower total radiation doses, the rates of Grade 3 or 4 toxicities are low but present. Particularly notable is that in our study however, revealed no evidence of Grade 3 or 4 GU or GI toxicity in both the acute or late effect profile thus far.

###### Comparison of GU and GI Toxicities in Selected TArials

  Study             RTOG 92-02          EORTC 22863        UK study      Norwegian study   NCI study
  ----------------- ------------------- ------------------ ------------- ----------------- -----------------------------
  Acute GU G 1, 2   529/758 (70%)                          71/79 (90%)   36/43 (84%)       8/12 (67%)
  Acute GU G 3, 4   25/758 (3%)         7%                 1/79 (1.3%)   1/43 (2%)         0%
  Acute GI G 1, 2   666/758 (88%)                          74/79 (94%)   34/43 (79%)       10/12 (83%)
  Acute GI G 3, 4   11/201 (5.5%)       5%                 1/79 (1.3%)   0%                0%
  Late GU G 1, 2    12.5% (Gr 2 only)   12.5% (Gr2 only)   2.5% (Gr 2)   20/43 (47%)       6/12 (50%), 25% (Gr 2 only)
  Late GU G 3, 4    3.4%                3.4%               2.5%          1/43 (2%)         0%
  Late GI G 1, 2    9.5% (Gr 2 only)    9.5% (Gr 2 only)   25%           22/43 (51%)       5/12(42%), 8% (Gr 2 only)
  Late GI G 3, 4    0.3%                0.3%               1.3%          0%                0%

The results in [Table 3](#T3){ref-type="table"} should be interpreted in the context of how CTV pelvic lymph nodes are defined in this trial and the previously referenced studies. The UK study, this CTV was defined as the uninvolved pelvic LN (obturator, internal iliac and external iliac chains bilaterally up to and including the common iliac region and pre-sacral nodes anterior to the first, second, and third sacral vertebrae) with no margin \[[@R18]\]. Our contouring of the LN groups is different: a radial 2 cm margin of the vessels (distal aorta, common, internal and external iliacs). This was based on a study that estimated that 94.5% of nodal failures were likely to be within 2 cm of these vessels. This study also demonstrates that 61% of the nodal failures were within 2 cm superior to the bifurcation and 10.2 cm inferior \[[@R23]\]. We, however, did not include the pre-sacral LN. The group from Norway had similar CTV to our group: 2.5 cm ring on the internal and external iliac vessels and did not include the pre-sacral LN \[[@R19]\]. At the time this Phase I trial was conceived, the current RTOG recommendations had not been available. We recognize that our nodal volumes differ from the current RTOG contouring atlas which recommends contouring from 7 mm around iliac vessels contouring out bladder, bowel, and bone; commence at distal common iliac vessels at L5/S1 interspace and to stop contouring at the top of the femoral heads; recommend treatment of presacral LN (subaortic only).

There has been controversy surrounding the role of pelvic RT in patients with a high risk of prostate cancer. There have been randomized studies to show the benefit of hormonal therapy in addition to RT (which included whole pelvic RT) but these did not address the benefit of elective whole pelvis irradiation \[[@R02]-[@R05]\]. There have been nonrandomized studies that address this question but with conflicting results \[[@R28]-[@R32]\]. While the initial results of RTOG 94-13 had been promising, the later follow-up failed to show an improvement in progression free survival \[[@R33]\]. The Groupe d'Etude des Tumeurs Uro-Genitales (GETUG) trial also showed no benefit for OS or PFS \[[@R34]\]. One of the possible reasons for this lack of benefit is postulated to be that a higher dose of radiation is needed to eradicate potential lymph node metastases. Our current study has moved on to the next cohort. Perhaps this dose escalation will address this theoretical concern of suboptimal pelvic nodal dosing.

Our results are interesting in that at this current follow-up, we have found that we can limit the dose to the small bowel, which has led to \[delete "a decrease in both"\] acceptable acute and late toxicities. In order to better assess the late term toxicity, we need a longer follow-up and investigate whether these results are sustainable for the long term. However, these current findings are encouraging that we can safely escalate to a higher dose. We adhered to the small bowel constraints as documented in the literature, but with longer follow-up these may be subject to modification. This Phase I trial has continued onto the next two cohorts where the lymph node groups receive 5040 cGy and 5400 cGy respectively, and we are hopeful that the side effect profile will be tolerable thus giving us the ability to reach higher doses to the pelvis with the use of image guided IMRT.

This work was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The views expressed do not necessarily represent the views of the National Institutes of Health or the United States Government.

Financial Disclosures {#s4a1}
=====================

Dr. Choyke has a research agreement (CRADA) with Philips. All other authors have no conflicts of interest to disclose.
